These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 38289658)
1. New Laser Treatment for Prurigo Nodularis. Pestoni Porvén C; Vieira Dos Santos V; Del Pozo Losada J Dermatol Surg; 2024 May; 50(5):495-497. PubMed ID: 38289658 [No Abstract] [Full Text] [Related]
2. Tofacitinib for Prurigo Nodularis: A Case Report. Peng C; Li C; Zhou Y; Wang Q; Xie P; Li T; Hao P Clin Cosmet Investig Dermatol; 2022; 15():503-506. PubMed ID: 35340735 [TBL] [Abstract][Full Text] [Related]
3. Treatment of idiopathic prurigo nodularis in Taiwanese patients with low-dose thalidomide. Lan CC; Lin CL; Wu CS; Chai CY; Chen WT; Chen GS J Dermatol; 2007 Apr; 34(4):237-42. PubMed ID: 17352720 [TBL] [Abstract][Full Text] [Related]
4. Prurigo nodularis: a review. Lee MR; Shumack S Australas J Dermatol; 2005 Nov; 46(4):211-18; quiz 219-20. PubMed ID: 16197418 [TBL] [Abstract][Full Text] [Related]
5. Epidemiology of Prurigo Nodularis compared with Psoriasis in Germany: A Claims Database Analysis. Ständer S; Ketz M; Kossack N; Akumo D; Pignot M; Gabriel S; Chavda R Acta Derm Venereol; 2020 Nov; 100(18):adv00309. PubMed ID: 33021323 [TBL] [Abstract][Full Text] [Related]
6. The Sleep Disturbance Numerical Rating Scale: Content Validity, Psychometric Validation, and Meaningful Within-Patient Change in Prurigo Nodularis. Ständer S; Fofana F; Dias-Barbosa C; Rodriguez D; Budhiarso I; Jabbar-Lopez ZK; Piketty C; Vernon M; Puelles J Dermatol Ther (Heidelb); 2023 Jul; 13(7):1587-1602. PubMed ID: 37329468 [TBL] [Abstract][Full Text] [Related]
7. [Prurigo nodularis: its association with dermatoses and systemic disorders]. Mettang T; Vonend A; Raap U Hautarzt; 2014 Aug; 65(8):697-703. PubMed ID: 25113328 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study. Sofen H; Bissonnette R; Yosipovitch G; Silverberg JI; Tyring S; Loo WJ; Zook M; Lee M; Zou L; Jiang GL; Paolini JF EClinicalMedicine; 2023 Mar; 57():101826. PubMed ID: 36816342 [TBL] [Abstract][Full Text] [Related]
9. Combination therapy of fexofenadine and montelukast is effective in prurigo nodularis and pemphigoid nodularis. Shintani T; Ohata C; Koga H; Ohyama B; Hamada T; Nakama T; Furumura M; Tsuruta D; Ishii N; Hashimoto T Dermatol Ther; 2014; 27(3):135-9. PubMed ID: 24102897 [TBL] [Abstract][Full Text] [Related]
10. Prevalence of Prurigo Nodularis in Poland. Ryczek A; Reich A Acta Derm Venereol; 2020 May; 100(10):adv00155. PubMed ID: 32421199 [TBL] [Abstract][Full Text] [Related]
11. Validation of the Peak Pruritus Numerical Rating Scale as a Patient-Reported Outcome Measure in Prurigo Nodularis. Kwatra SG; Rodriguez D; Dias-Barbosa C; Budhiarso I; Fofana F; Vernon M; Gabriel S; Piketty C; Puelles J Dermatol Ther (Heidelb); 2023 Oct; 13(10):2403-2416. PubMed ID: 37615836 [TBL] [Abstract][Full Text] [Related]
12. Impact of Chronic Kidney Disease Severity on the Risk of Prurigo Nodularis: A Population-Based Cohort Study. Kim HS; Kim HJ; Ahn HS Acta Derm Venereol; 2022 Sep; 102():adv00781. PubMed ID: 35971831 [TBL] [Abstract][Full Text] [Related]
13. Aberrant Expression of Histamine-independent Pruritogenic Mediators in Keratinocytes may be Involved in the Pathogenesis of Prurigo Nodularis. Zhong W; Wu X; Zhang W; Zhang J; Chen X; Chen S; Huang H; Yang Y; Yu B; Dou X Acta Derm Venereol; 2019 May; 99(6):579-586. PubMed ID: 30809683 [TBL] [Abstract][Full Text] [Related]
14. Predictive values of prurigo nodularis and herpes zoster for HIV infection and immunosuppression requiring HAART in French Guiana. Magand F; Nacher M; Cazorla C; Cambazard F; Marie DS; Couppié P Trans R Soc Trop Med Hyg; 2011 Jul; 105(7):401-4. PubMed ID: 21621233 [TBL] [Abstract][Full Text] [Related]